The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains.
Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.
Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.
With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry.
A new EU regulation on implantable medical devices takes steps to acknowledge that patient outcomes and safety are primary goals, but the transition to the new system might not be easy for industry stakeholders, says Jo Emmett of Premier Research.
European developments surrounding the patentability of plants and animals have become rather political, but there are ways for patentees to mitigate the effects of political influence over the patenting process, writes Jane Wainwright of Potter Clarkson.
Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.
It appears necessary and perhaps inevitable that further guidance from the UK Court of Appeal will be provided on the issue of second medical use patents, following the high-profile dispute between Warner-Lambert and Actavis. Geoff Hussey and Christopher Burnett of AA Thornton & Co report.
A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.
Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.